(NASDAQ: ETON) Eton Pharmaceuticals's forecast annual revenue growth rate of 41.18% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 35.65%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.42%.
Eton Pharmaceuticals's revenue in 2026 is $71,141,000.On average, 5 Wall Street analysts forecast ETON's revenue for 2026 to be $2,812,354,895, with the lowest ETON revenue forecast at $2,657,027,733, and the highest ETON revenue forecast at $2,988,009,750. On average, 5 Wall Street analysts forecast ETON's revenue for 2027 to be $3,778,054,331, with the lowest ETON revenue forecast at $3,316,792,729, and the highest ETON revenue forecast at $4,258,892,733.
In 2028, ETON is forecast to generate $5,368,334,156 in revenue, with the lowest revenue forecast at $4,179,244,654 and the highest revenue forecast at $6,574,318,705.